The Clinical Efficacy and Safety of Gumiganghwal-Tang in Knee Osteoarthritis: A Phase II Randomized Double Blind Placebo Controlled Study
Table 4
Comparisons of secondary efficacy.
GMGHT group (n= 61)
Placebo group (n= 66)
p value
Change in patient’s global assessment from baseline
week
-10.4 (10.8)
-1.7 (5.8)
2.50 x 10−7
week
-17.4 (19.0)
-4.5 (6.6)
3.24 x 10−6
week
-22.5 (20.7)
-9.0 (12.8)
3.04 x 10−5
Change in patient’s pain assessment from baseline
week
-11.1 (11.0)
-2.2 (5,2)
1.32 x 10−7
week
-17.5 (19.7)
-5.4 (6.6)
2.07 x 10−5
week
-22.4 (21.3)
-9.6 (14.4)
1.62 x 10−4
Change in physician’s global assessment from baseline
week
-13.3 (12.0)
-0.5 (6.1)
4.67 x 10−11
week
-21.0 (19.4)
-1.8 (8.3)
3.89 x 10−10
week
-23.8 (20.9)
-7.9 (16.9)
6.57 x 10−6
Change in pain WOMAC score from baseline
week
-2.8 (2.6)
-0.7 (1.8)
1.45 x 10−6
week
-3.9 (4.0)
-1.2 (2.0)
8.12 x 10−6
week
-4.5 (4.0)
-1.7 (2.4)
6.82 x 10−6
Change in stiffness WOMAC score from baseline
week
-0.2 (1.4)
-0.1 (1.3)
0.75
week
-1.6 (1.6)
-0.7 (1.3)
1.27 x 10−3
week
-1.6 (1.6)
-1.3 (1.7)
0.22
Change in function WOMAC score from baseline
week
-7.3 (8.6)
-1.7 (3.0)
7.49 x 10−6
week
-12.8 (12.2)
-2.2 (3.3)
7.16 x 10−9
week
-15.0 (12.8)
-4.2 (5.3)
3.26 x 10−8
Values are presented as mean (SD) unless otherwise stated. GMGHT: Gumiganghwal-tang, SD: standard deviation, WOMAC: the Western Ontario and McMaster Universities Arthritis Index.
